Drug Trial Radar · NCT03592472
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
Last checked: Nov 19, 2026Latest source record: Apr 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
413
Planned (sponsor's estimate)
Start
Jul 17, 2018
Primary completion
Dec 30, 2026
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Xynomic Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 19, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).
Conditions
- Renal Cell Carcinoma
Interventions
PazopanibDrug
All patients will receive pazopanib at a starting dose of 800 mg by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle. Patients should be instructed to take their once- daily oral dose of pazopanib at the same time each morning. Each dose of pazopanib should be taken with an 8 oz/240 mL glass of water either 1 hour before or 2 hours after a meal. Patients should be instructed to swallow the tablets whole and not chew them.
AbexinostatDrug
The starting dose and schedule of abexinostat will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Each dose of abexinostat should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart. Patients should be instructed to swallow the tablets whole and not chew them.
PlaceboOther
The starting dose and schedule of abexinostat matching placebo will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Each dose of placebo should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart. Patients should be instructed to swallow the tablets whole and not chew them.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: From randomization date to date of first documentation of progression OR death (up to approximately 4 years).
Locations
38 sites in 6 countries. Site status is shown where the registry gives one.
University Of UA Cancer Center(UACC)/DH-SJHMC
Phoenix, Arizona · Withdrawn
University of California Davis Comprehensive Cancer Center
Sacramento, California · Withdrawn
UCSF Helen Diller Family Comphrensive Cancer Center - Hemato
San Francisco, California · Withdrawn
Norton Cancer Institute, Norton Healthcare Pavilion
Louisville, Kentucky · Completed
Ochsner Clinic Foundation
New Orleans, Louisiana · Completed
GU Research Network/Urology Cancer Center
Omaha, Nebraska · Withdrawn
Nebraska Cancer Specialists
Omaha, Nebraska · Completed
Northwell Health/Monter Cancer Center
Lake Success, New York · Withdrawn
Mainstreet Physicans Care
Rochester, New York · Completed
Precision Cancer Research/Dayton Physicians Network - Treatment
Kettering, Ohio · Withdrawn
Oregon Health and Science University
Portland, Oregon · Completed
St. Luke's Hospital
Easton, Pennsylvania · Completed
HOPE Cancer Center of East Texas
Tyler, Texas · Completed
Medical Oncology Associates, PS (dba Summit Cancer Centers)
Spokane, Washington · Withdrawn
Beijing Cancer Hospital
Beijing, China · Recruiting
Zhongshan Hospital Affiliated to Fudan University
Shanghai, China · Not yet recruiting
Fondazione del Piemonte per l'Oncologia_Istituto di Candiolo, IRCCS_ Oncologia Medica
Candiolo, Italy · Withdrawn
A.O. Cannizzaro_UOS Oncologia Medica
Catania, Italy · Withdrawn
IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) UO Oncologia Medica
Meldola (FC), Italy · Withdrawn
Istituto Europeo di Oncologia_Unità Oncologia Medica Urogenitale e Cervico Facciale
Milan, Italy · Withdrawn
Istituto Nazionale dei Tumori-Fondazione Pascale- SC Oncologia Medica
Naples, Italy · Withdrawn
Azienda Ospedaliero-Universitaria Maggiore della Carità Novara_SC Oncologia Medica
Novara, Italy · Withdrawn
Istituti Clinici Scientifici Maugeri Spa-SB_ UO Oncologia Medica
Pavia, Italy · Withdrawn
Azienda Ospedaliero Universitaria Pisana_ UO Oncologia Medica Universitaria
Pisa, Italy · Withdrawn
Fondazione Policlinico Universitario A. Gemelli, U.O.C. Oncologia Medica
Roma, Italy · Withdrawn
Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny
Brzozów, Poland · Withdrawn
Szpitale Pomorskie Sp. z o.o. Oddział Onkologii i Radioterapii
Gdynia, Poland · Withdrawn
Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie Sp. z o.o. Oddział Onkologii Klinicznej z Pododdziałem Dziennym
Krakow, Poland · Completed
Clinical Research Center Sp. z o.o., Medic-R Sp. K.
Poznan, Poland · Withdrawn
National Cancer Center - Center For Prostate Cancer
Goyang-si, South Korea · Completed
CHA Bundang Medical Center, CHA University
Seongnam-si, South Korea · Completed
Severance Hospital, Yonsei University Health System - Medical Oncology
Seoul, South Korea · Completed
Asan Medical Center - University of Ulsan College of Medicin
Seoul, South Korea · Completed
Samsung Medical Center - Hematology-Oncology
Seoul, South Korea · Withdrawn
H.G.U. de Elche
Elche, Spain · Withdrawn
Hospital Universitario Fundación Jiménez Díaz
Madrid, Spain · Withdrawn
Hospital Universitario 12 de Octubre
Madrid, Spain · Completed
H.U. Virgen de la Victoria
Málaga, Spain · Withdrawn
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.